Allergy Therapeutics Statistics

Total Valuation

Allergy Therapeutics has a market cap or net worth of GBP 243.59 million. The enterprise value is 261.66 million.

Market Cap	243.59M
Enterprise Value	261.66M

Important Dates

The next estimated earnings date is Tuesday, December 24, 2024.

Earnings Date	Dec 24, 2024
Ex-Dividend Date	n/a

Share Statistics

Allergy Therapeutics has 4.78 billion shares outstanding. The number of shares has increased by 458.41% in one year.

Current Share Class	n/a
Shares Outstanding	4.78B
Shares Change (YoY)	+458.41%
Shares Change (QoQ)	+75.22%
Owned by Insiders (%)	0.21%
Owned by Institutions (%)	2.73%
Float	235.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.46
PB Ratio	65.72
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.51
EV / Sales	4.74
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.36

Financial Position

The company has a current ratio of 1.63, with a Debt / Equity ratio of 8.35.

Current Ratio	1.63
Quick Ratio	0.93
Debt / Equity	8.35
Debt / EBITDA	n/a
Debt / FCF	-0.87
Interest Coverage	-9.06

Financial Efficiency

Return on equity (ROE) is -1,392.76% and return on invested capital (ROIC) is -58.99%.

Return on Equity (ROE)	-1,392.76%
Return on Assets (ROA)	-32.61%
Return on Capital (ROIC)	-58.99%
Revenue Per Employee	90,194
Profits Per Employee	-65,712
Employee Count	612
Asset Turnover	0.84
Inventory Turnover	2.09

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +200.58% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+200.58%
50-Day Moving Average	4.95
200-Day Moving Average	4.14
Relative Strength Index (RSI)	46.12
Average Volume (20 Days)	359,841

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Allergy Therapeutics had revenue of GBP 55.20 million and -40.22 million in losses. Loss per share was -0.01.

Revenue	55.20M
Gross Profit	29.74M
Operating Income	-34.34M
Pretax Income	-39.17M
Net Income	-40.22M
EBITDA	-30.02M
EBIT	-34.34M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 12.92 million in cash and 30.99 million in debt, giving a net cash position of -18.07 million or -0.00 per share.

Cash & Cash Equivalents	12.92M
Total Debt	30.99M
Net Cash	-18.07M
Net Cash Per Share	-0.00
Equity (Book Value)	3.71M
Book Value Per Share	0.00
Working Capital	12.94M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -32.14 million and capital expenditures -3.40 million, giving a free cash flow of -35.54 million.

Operating Cash Flow	-32.14M
Capital Expenditures	-3.40M
Free Cash Flow	-35.54M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross margin is 53.87%, with operating and profit margins of -62.20% and -72.86%.

Gross Margin	53.87%
Operating Margin	-62.20%
Pretax Margin	-70.95%
Profit Margin	-72.86%
EBITDA Margin	-54.38%
EBIT Margin	-62.20%
FCF Margin	-64.38%

Dividends & Yields

Allergy Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-458.41%
Shareholder Yield	-458.41%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Allergy Therapeutics has an Altman Z-Score of -4.01. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.01
Piotroski F-Score	n/a